Solvonis Therapeutics PLC (LSE:SVNS) has taken an important step forward in its mission to develop new treatments for high-burden central nervous system disorders, with its novel drug candidate SVN-015 accepted into a prestigious programme run by the US National Institute on Drug Abuse (NIDA). In this interview, CEO Anthony Tennyson explains to Proactive's Fouad Haidar why this milestone matters, not only for the company, but for millions of people affected by stimulant use disorder.
SVN-015 was discovered through Solvonis’ AI-driven drug discovery platform and is being developed as a potential treatment for methamphetamine and cocaine use disorder, conditions that impact around 2.5 million people in the US, yet currently have no approved medicines. Acceptance into NIDA’s Addiction Treatment Discovery Program gives Solvonis access to £3–5 million worth of non-dilutive, early-stage research, including both cardio-risk testing and preclinical efficacy studies.
Tennyson also outlines how successful completion of this programme could position Solvonis for a further $3 million per year over five years in NIH funding — support that could carry SVN-015 through its full preclinical package and into first-in-human trials.
In this conversation, he discusses the science behind SVN-015, the scale of the unmet medical need, and why this development marks a major opportunity for the company and the patients it aims to help.
#Solvonis #BiotechNews #DrugDiscovery #CNSDisorders #AddictionTreatment #NIDA #NIHFunding #StimulantUseDisorder #HealthcareInnovation #InvestingInBiotech
